MNPR — Monopar Therapeutics Share Price
0.000.00%
Last trade - 00:00- $11.17m
- $3.91m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 2 | ||
| Price to Tang. Book | 2 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -158.04% | ||
| Return on Equity | -107.19% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Monopar Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for cancer patients. The Company is building a drug candidate pipeline through in-house development as well as the licensing and acquisition of therapeutics in late preclinical and in clinical development stages. The Company has several compounds in development, which include MNPR-101-Zr, MNPR-101-RIT, Camsirubicin and MNPR-202. MNPR-101-Zr is a clinical-stage urokinase plasminogen activator receptor (uPAR)-targeted radio diagnostic imaging agent. MNPR-101-RIT is a late preclinical stage radiotherapeutic for advanced cancers. Camsirubicin is an analog of doxorubicin which has been designed to reduce the cardiotoxic side effects generated by doxorubicin while retaining effective anti-cancer activity. MNPR-202 is an early-stage analog of camsirubicin designed to potentially treat doxorubicin- and camsirubicin-resistant cancers.
Directors
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- December 5th, 2014
- Public Since
- December 19th, 2019
- No. of Shareholders
- 3,200
- No. of Employees
- 10
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Capital Market
- Shares in Issue
- 17,454,925
- Address
- 1000 Skokie Blvd Ste 350, WILMETTE, 60091-1146
- Web
- https://www.monopartx.com/
- Phone
- +1 8473880349
- Auditors
- BPM LLP
Upcoming Events for MNPR
Q2 2024 Monopar Therapeutics Inc Earnings Release
Similar to MNPR
180 Life Sciences
NASDAQ Capital Market
Abeona Therapeutics
NASDAQ Capital Market
ABVC Biopharma
NASDAQ Capital Market
Acesis Holdings
NASDAQ Capital Market
Achieve Life Sciences
NASDAQ Capital Market
FAQ
What is the Monopar Therapeutics share price?
As of Today at 19:14 UTC, shares in Monopar Therapeutics are trading at $0.64. This share price information is delayed by 15 minutes.
How has the Monopar Therapeutics share price performed this year?
Shares in Monopar Therapeutics last closed at $0.64 and the price had moved by -47.96% over the past 365 days. In terms of relative price strength the Monopar Therapeutics share price has underperformed the S&P500 Index by -56.69% over the past year.
What are the analyst and broker recommendations for Monopar Therapeutics?
The overall consensus recommendation for Monopar Therapeutics is Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the Monopar Therapeutics dividend yield?
Monopar Therapeutics does not currently pay a dividend.
Does Monopar Therapeutics pay a dividend?
Monopar Therapeutics does not currently pay a dividend.
When does Monopar Therapeutics next pay dividends?
Monopar Therapeutics does not currently pay a dividend.
How do I buy Monopar Therapeutics shares?
To buy shares in Monopar Therapeutics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Monopar Therapeutics?
As of the previous close price of $0.64, shares in Monopar Therapeutics had a market capitalisation of $11.17m.
Where are Monopar Therapeutics shares listed?
Here are the trading details for Monopar Therapeutics:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: MNPR
What kind of share is Monopar Therapeutics?
Based on an overall assessment of its quality, value and momentum Monopar Therapeutics is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Monopar Therapeutics share price forecast for 2024?
The analyst consensus target price for shares in Monopar Therapeutics is $2.00. That is 212.45% above the last closing price of $0.64.
Analysts covering Monopar Therapeutics currently have a consensus Earnings Per Share (EPS) forecast of -$0.50 for the next financial year.
What is the trend in the Monopar Therapeutics share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Monopar Therapeutics. Over the past six months, its share price has outperformed the S&P500 Index by +19.12%.
As of the last closing price of $0.64, shares in Monopar Therapeutics were trading +12.03% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Monopar Therapeutics PE Ratio?
The Monopar Therapeutics PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.64.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Monopar Therapeutics?
We do not have data on Monopar Therapeutics' directors